<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04670575</url>
  </required_header>
  <id_info>
    <org_study_id>VIVA</org_study_id>
    <nct_id>NCT04670575</nct_id>
  </id_info>
  <brief_title>Vivity Outcomes in Patients With Early Stage Glaucoma</brief_title>
  <acronym>VIVA</acronym>
  <official_title>Vivity Outcomes in Patients With Early Stage Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vance Thompson Vision</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vance Thompson Vision</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the study is to determine the visual outcomes in patients with mild,&#xD;
      pre-perimetric glaucoma who undergo cataract surgery with implantation of the Alcon Vivity&#xD;
      Extended Range Intraocular Lens (IOL).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Uncorrected Distance Visual Acuity</measure>
    <time_frame>4-6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Uncorrected Intermediate Visual Acuity</measure>
    <time_frame>4-6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Uncorrected Near Visual Acuity</measure>
    <time_frame>4-6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Contrast Sensitivity</measure>
    <time_frame>4-6 months</time_frame>
    <description>As measured by Pelli Robson Chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction and Spectacle Independence Survey Results</measure>
    <time_frame>4-6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Refractive Spherical Equivalent</measure>
    <time_frame>4-6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Glaucoma</condition>
  <condition>Cataract</condition>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>Vivity</arm_group_label>
    <description>Patients implanted with Vivity or Vivity Toric intraocular lens at the time of cataract surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cataract Surgery with Implantation of Vivity Extended Range of Vision IOL</intervention_name>
    <description>Patients with early stage glaucoma implanted with Vivity or Vivity Toric IOL</description>
    <arm_group_label>Vivity</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with early stage glaucoma with cataracts in both eyes who are planned to have&#xD;
        bilateral cataract surgery with implantation of Vivity or Vivity Toric intraocular lens.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients at least age 45 years of age undergoing uncomplicated cataract surgery with&#xD;
             optional concomitant minimally invasive glaucoma surgery (MIGS)&#xD;
&#xD;
          2. Subjects with documented diagnosis of pre-perimetric glaucoma&#xD;
&#xD;
          3. Calculated lens power within Vivity/Vivity toric range&#xD;
&#xD;
          4. Willing and able to comprehend informed consent and complete 4-6 month post-op visit&#xD;
&#xD;
          5. Potential postoperative BCDVA of 20/20 or better in each eye based on Investigator's&#xD;
             medical opinion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ocular comorbidity, other than pre-perimetric glaucoma, that could reduce the&#xD;
             potential postoperative BCDVA&#xD;
&#xD;
          2. Previous ocular surgery including refractive surgery&#xD;
&#xD;
          3. Subjects who are pregnant or plan to become pregnant during the course of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Brian M Shafer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vance Thompson Vision</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Keeley Puls</last_name>
    <phone>402 740 9420</phone>
    <email>Keeley.puls@vancethompsonvision.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vance Thompson Vision</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 13, 2020</study_first_submitted>
  <study_first_submitted_qc>December 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>December 13, 2020</last_update_submitted>
  <last_update_submitted_qc>December 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Extended Range of Vision, Intraocular Lens Technology, Glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

